Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-γ ligands

Journal of Laboratory and Clinical Medicine

Volumn 140, Issue 1, 2002, Pages 17-26

  Rumi, Mohammad Azharul Karim ^a   Sato, Hiroshi ^a   Ishihara, Shunji ^a   Ortega, Cesar ^a   Kadowaki, Yasunori ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; CHROMAN DERIVATIVE; LIGAND; MESSENGER RNA; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; TROGLITAZONE;

ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; DNA REPLICATION; DRUG EFFECT; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DIVISION; CHROMANS; DNA REPLICATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0036633930     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2002.125055     Document Type: Article

References (50)

1. Peroxisome proliferator-activated receptor (PPAR) γ: Adipose-predominant expression and induction early in adipocyte differentiation
2. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
3. Adipogenesis and obesity: Rounding out the big picture
4. Terminal differentiation of human liposarcoma cells by ligands for peroxisome proliferator-activated receptor and retinoid X receptor
5. Activation of PPARγ leads to inhibition of anchorage independent growth of human colorectal cancer cells
6. Troglitazone suppress cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor
7. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells
8. Terminal differentiation of human breast cancer through PPAR γ
9. Differentiation and reversal of malignant changes in colon cancer through PPARγ
10. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer
11. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARγ) in human neuroblastoma cells
12. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
13. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells
14. 15-Deoxy-delta (12, 14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor γ, induces apoptosis in JEG3 choriocarcinoma cells
15. Activation of PPARγ inhibits cell growth and apoptosis in human gastric cancer cells
16. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
17. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPARγ) GW7845, inhibits rat mammary carcinogenesis
18. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma
19. Effects of ligand activation of peroxisome proliferator-activated receptor γin human prostate cancer
20. Down-regulation of prostate specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer
21. Cancer statistics, 1997
22. Multimodal therapy for squamous carcinoma of the esophagus
23. Cytokine mRNA expression patterns in human esophageal cancer cell lines
24. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer
25. Low interleukin-1 α messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma
26. Opposing effects of IL-1α and IL-1β on malignancy patterns: Tumor cell-associated IL-1α potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness
27. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T and T.Tn) established from the oral tumor
28. Establishment of a parathyroid hormone-like factor-producing esophageal carcinoma cell line (EC-GI)
29. Production of interleukin-1 alpha and a parathyroid hormone-like factor by squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia
30. PPARγinhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets
31. Troglitazone: A review of its use in the management of type 2 diabetes mellitus
32. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
33. Cytokines and chemokines are both expressed by human myoblasts: Possible relevance for the immune pathogenesis of muscle inflammation
34. Molecular cloning, expression and characterization of human peroxisome proliferator-activated receptors γ1 and γ2
35. cDNA cloning of IL-1α and IL-1β from mRNA of U937 cell line
36. Hepatic dysfunction associated with troglitazone
37. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
38. From the Food and Drug Administration: New type 2 diabetes drugs
39. Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPAR γ agonists
40. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells
41. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits the β2 intergrin-dependent oxidative burst: Involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation
42. Cyclopentenone prostaglandins: New allies in the war on inflammation
43. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
44. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NFκB signaling pathway
45. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
46. Growth inhibition of myeloid leukemia cells by troglitazone a ligand for peroxisome proliferator activated receptor gamma and retinoids
47. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis
48. PPARγ agonists inhibit production of monocyte inflammatory cytokines
49. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo
50. The role of PPARγ in macrophage differentiation and cholesterol uptake